Lantern Pharma (LTRN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Lantern Pharma (LTRN) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.34 of bullish evidence against -0.48 bearish.

Lantern Pharma last closed at $0.81, -2.41% on the session.

Against the IVW growth benchmark the position is -3.21% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for LTRN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Lantern Pharma in the 2nd percentile on return on equity, where 100 is best.

Lantern Pharma is classified under Health Care / Biotechnology, with a market capitalisation of $12.40M.

StockMap tracks Lantern Pharma as the 349th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Lantern Pharma ranks 348th of 381 in the group, against a group median of -0.08.